CRSP
Price
$38.57
Change
+$0.52 (+1.37%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
3.33B
67 days until earnings call
KALV
Price
$13.80
Change
+$0.26 (+1.92%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
686.32M
28 days until earnings call
Interact to see
Advertisement

CRSP vs KALV

Header iconCRSP vs KALV Comparison
Open Charts CRSP vs KALVBanner chart's image
CRISPR Therapeutics AG
Price$38.57
Change+$0.52 (+1.37%)
Volume$51.35K
Capitalization3.33B
KalVista Pharmaceuticals
Price$13.80
Change+$0.26 (+1.92%)
Volume$7.42K
Capitalization686.32M
CRSP vs KALV Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. KALV commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and KALV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (CRSP: $38.05 vs. KALV: $13.54)
Brand notoriety: CRSP and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 66% vs. KALV: 87%
Market capitalization -- CRSP: $3.33B vs. KALV: $673.15M
CRSP [@Biotechnology] is valued at $3.33B. KALV’s [@Biotechnology] market capitalization is $673.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, KALV is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while KALV’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 2 bearish.
  • KALV’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than KALV.

Price Growth

CRSP (@Biotechnology) experienced а +2.22% price change this week, while KALV (@Biotechnology) price change was +20.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +9.95%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

KALV is expected to report earnings on Sep 04, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.33B) has a higher market cap than KALV($686M). KALV YTD gains are higher at: 59.858 vs. CRSP (-3.328). KALV has higher annual earnings (EBITDA): -173.23M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. KALV (253M). KALV has less debt than CRSP: KALV (5.78M) vs CRSP (219M). CRSP has higher revenues than KALV: CRSP (35M) vs KALV (0).
CRSPKALVCRSP / KALV
Capitalization3.33B686M486%
EBITDA-455.24M-173.23M263%
Gain YTD-3.32859.858-6%
P/E RatioN/AN/A-
Revenue35M0-
Total Cash1.86B253M733%
Total Debt219M5.78M3,788%
FUNDAMENTALS RATINGS
CRSP vs KALV: Fundamental Ratings
CRSP
KALV
OUTLOOK RATING
1..100
89
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9296
PRICE GROWTH RATING
1..100
8043
P/E GROWTH RATING
1..100
79100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALV's Valuation (55) in the Pharmaceuticals Other industry is in the same range as CRSP (65) in the Biotechnology industry. This means that KALV’s stock grew similarly to CRSP’s over the last 12 months.

KALV's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as CRSP (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (92) in the Biotechnology industry is in the same range as KALV (96) in the Pharmaceuticals Other industry. This means that CRSP’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRSP (80) in the Biotechnology industry. This means that KALV’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (79) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that CRSP’s stock grew similarly to KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPKALV
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MPGLX11.54N/A
N/A
MassMutual Disciplined Gr Adm
FVLAX20.10N/A
N/A
Fidelity Advisor Value Leaders A
WOFNX59.83N/A
N/A
Allspring Opportunity Inst
MSFKX19.17N/A
N/A
MFS Total Return R6
BCSKX9.23N/A
N/A
BlackRock Commodity Strategies K

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+1.42%
ATXS - KALV
47%
Loosely correlated
+6.45%
IDYA - KALV
47%
Loosely correlated
-2.50%
TRDA - KALV
45%
Loosely correlated
-3.76%
CRSP - KALV
45%
Loosely correlated
+0.03%
KYMR - KALV
45%
Loosely correlated
+1.56%
More